0
Catégories
Documents disponibles dans cette catégorie (18)
Ajouter le résultat dans votre panier Affiner la recherche
Titre : Association between e-cigarettes use and myocardial infarction : a systematic review and meta-analysis Type de document : document électronique Auteurs : Muhammad Talal Ashraf, Auteur ; Asim Shaikh, Auteur ; Muhammad Khuzzaim Shakeel Khan, Auteur Editeur : Springer Année de publication : 2023 Collection : The Egyptian Heart Journal num. 75(95) Importance : 8 p. Présentation : ill., graph.; tab. Langues : Anglais (eng) Catégories : [TABAC] chimie du tabac:tabac fumé:cigarette:cigarette électronique
[TABAC] étude:méta-analyse
[TABAC] tabagisme:pathologie:pathologie cardio-vasculaire:infarctus du myocarde
[TABAC] tabagisme:risque
[TABAC] tabagisme:tabagisme actifIndex. décimale : TA 3.2.2.5 Pathologies cardiovasculaires Résumé : Background
The popularity of e-cigarettes has risen dramatically over the last few years, particularly among the younger population. Although the use of combustible cigarettes has established evidence to be associated with the development of several adverse cardiopulmonary diseases, the investigations regarding the prospective long-term effects of e-cigarette use on the cardiovascular system have just begun. We set to investigate if there is an association between the history of MI and e-cigarette use among smokers and non-smokers?
Methods
The current review aims to assess the association of myocardial infarction with e-cigarette consumption. PubMed, Google Scholar, and Cochrane Central Register of Controlled Trials (CENTRAL) were queried up to October 2022 to identify articles assessing the incidence of myocardial infarction among e-cigarette users. Data were meta-analyzed using a random-effects model to derive odds ratios (OR) and 95% confidence intervals.
Results
Nine studies involving 984,764 patients were included. The mean age of e-cigarette smokers was less than the controls, and female participants dominated the sample size. E-cigarette users were associated with increased odds of MI than non-users [OR = 1.44; 95% CI (1.22, 1.74); P < 0.0001]. Dual users were also associated with increased odds of MI with large effect when compared to non-users [OR = 4.04; 95% CI (3.40, 4.81); P < 0.00001].
Conclusions
Dual use is associated with an increased risk of MI than e-cigarette use only. Similarly, dual and solely e-cigarette consumption patterns of nicotine delivery are at a higher risk of MI than non-smokers.En ligne : https://doi.org/10.1186/s43044-023-00426-6 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10599 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Comparative systematic review on the safety of e-cigarettes and conventional cigarettes / Josef Yayan (2024)
Titre : Comparative systematic review on the safety of e-cigarettes and conventional cigarettes Type de document : document électronique Auteurs : Josef Yayan, Auteur ; Karl-Josef Franke, Auteur ; Christian Biancosino, Auteur ; Kurt Rasche, Auteur Editeur : Elsevier Science Direct Année de publication : 2024 Collection : Food and chemical toxicology, ISSN 1873-6351 num. 185 Importance : p. 1-6 Présentation : ill. Langues : Anglais (eng) Catégories : [TABAC] chimie du tabac:substance toxique
[TABAC] chimie du tabac:tabac fumé:cigarette
[TABAC] chimie du tabac:tabac fumé:cigarette:cigarette électronique
[TABAC] étude:méta-analyse
[TABAC] tabagisme:risqueIndex. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) Résumé : Background
This systematic review evaluated the health risks of electronic cigarettes (e-cigarettes) compared to traditional cigarettes. It examines various studies and research on the subject to provide a comprehensive analysis of potential health risks associated with both smoking methods.
Methods
The systematic review, incorporating searches in PubMed, Scopus, Web of Science, and the Cochrane Library up to July 2023, examines the results obtained in relevant studies, and provides a critical discussion of the results.
Results
E-cigarettes exhibit reduced exposure to harmful toxins compared to traditional cigarettes.
Conclusion
However, concerns persist regarding respiratory irritation and potential health risks, especially among youth, emphasizing the need for comprehensive, long-term research and protective legislation.En ligne : https://doi.org/10.1016/j.fct.2024.114507 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10539 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : E-cigarettes and smoking cessation in real-world and clinical settings : a systematic review and meta-analysis Type de document : document électronique Auteurs : Sara Kalkhoran, Auteur ; Stanton A. Glantz, Auteur Editeur : Lancet Année de publication : 2016 Collection : The Lancet Respiratory Medicine, ISSN 2213-2600 num. 4(2) Importance : p.116-128 Langues : Anglais (eng) Catégories : [TABAC] chimie du tabac:tabac fumé:cigarette:cigarette électronique
[TABAC] étude:méta-analyse
[TABAC] sevrage tabagiqueIndex. décimale : TA 6.2.3.2 Autres produits En ligne : https://doi.org/10.1016/s2213-2600(15)00521-4 Format de la ressource électronique : HTML, PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9428 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Effect of smoke-free workplaces on smoking behaviour: systematic review / Caroline Fichtenberg (2002)
Titre : Effect of smoke-free workplaces on smoking behaviour: systematic review Type de document : texte imprimé Auteurs : Caroline Fichtenberg, Auteur ; Stanton A. Glantz, Auteur Editeur : BMJ Publishing Group Année de publication : 2002 Collection : British Medical Journal num. 325:188 Importance : 7 p. Langues : Anglais (eng) Catégories : [TABAC] économie du tabac:industrie:cigarettier
[TABAC] étude:méta-analyse
[TABAC] législation:milieu réglementé:lieu de travail
[TABAC] prévention:environnement sans fumée
[TABAC] tabagisme:aspect économique:coût du tabagisme:coût pour la sociétéIndex. décimale : TA 7.8 Lieux non-fumeurs Résumé : Objective: To quantify the effects of smoke-free workplaces on smoking in employees and compare these effects to those achieved through tax increases.
Design: Systematic review with a random effects meta-analysis.
Study selection: 26 studies on the effects of smoke-free workplaces
Setting: Workplaces in the United States, Australia, Canada, and Germany
Participants: Employees in unrestricted and totally smoke-free workplaces
Main outcome measures: Daily cigarette consumption (per smoker and per employee) and smoking prevalence
Results: Totally smoke-free workplaces are associated with reductions in prevalence of smoking of 3.8% (95% confidence interval 2.8% to 4.7%) and 3.1 (2.4 to 3.8) fewer cigarettes smoked per day per continuing smoker. Combination of the effects of reduced prevalence and lower consumption per continuing smoker yields a mean reduction of 1.3 cigarettes per day per employee, which corresponds to a relative reduction of 29%. To achieve similar reductions the tax on a pack of cigarettes would have to increase from $0.76 to $3.05 (€0.78 to €3.14) in the United States and from £3.44 to £6.59 (€5.32 to €10.20) in the United Kingdom. If all workplacesbecame smoke-free, consumption per capita in the entire population would drop by 4.5% in the United States and 7.6% in the United Kingdom, costing the tobacco industry $1.7 billion and £310 million annually in lost sales. To achieve similar reductions tax per pack would have to increase to $1.11 and £4.26
Conclusions: Smoke-free workplaces not only protect non-smokers from the dangers of passive smoking, they also encourage smokers to quit or to reduce consumptionEn ligne : https://www.bmj.com/content/325/7357/188.long Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8111 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Effectiveness of smoking cessation therapies : a systematic review and meta-analysis Type de document : texte imprimé Auteurs : Ping Wu, Auteur ; Kumanan Wilson, Auteur ; Popey Dimoulas, Auteur Editeur : BioMed Central Année de publication : 2006 Collection : BMC Public Health num. Vol. 6 Importance : 16 p. Présentation : tab., ill. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] étude:méta-analyse
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:bupropion
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3 Approche pharmacologique Résumé : BACKGROUND:
Smoking remains the leading preventable cause of premature deaths. Several pharmacological interventions now exist to aid smokers in cessation. These include Nicotine Replacement Therapy [NRT], bupropion, and varenicline. We aimed to assess their relative efficacy in smoking cessation by conducting a systematic review and meta-analysis.
METHODS:
We searched 10 electronic medical databases (inception to Sept. 2006) and bibliographies of published reviews. We selected randomized controlled trials [RCTs] evaluating interventions for smoking cessation at 1 year, through chemical confirmation. Our primary endpoint was smoking cessation at 1 year. Secondary endpoints included short-term smoking cessation (approximately 3 months) and adverse events. We conducted random-effects meta-analysis and meta-regression. We compared treatment effects across interventions using head-to-head trials and when these did not exist, we calculated indirect comparisons.
RESULTS:
We identified 70 trials of NRT versus control at 1 year, Odds Ratio [OR] 1.71, 95% Confidence Interval [CI], 1.55-1.88, P =< 0.0001). This was consistent when examining all placebo-controlled trials (49 RCTs, OR 1.78, 95% CI, 1.60-1.99), NRT gum (OR 1.60, 95% CI, 1.37-1.86) or patch (OR 1.63, 95% CI, 1.41-1.89). NRT also reduced smoking at 3 months (OR 1.98, 95% CI, 1.77-2.21). Bupropion trials were superior to controls at 1 year (12 RCTs, OR1.56, 95% CI, 1.10-2.21, P = 0.01) and at 3 months (OR 2.13, 95% CI, 1.72-2.64). Two RCTs evaluated the superiority of bupropion versus NRT at 1 year (OR 1.14, 95% CI, 0.20-6.42). Varenicline was superior to placebo at 1 year (4 RCTs, OR 2.96, 95% CI, 2.12-4.12, P =< 0.0001) and also at approximately 3 months (OR 3.75, 95% CI, 2.65-5.30). Three RCTs evaluated the effectiveness of varenicline versus bupropion at 1 year (OR 1.58, 95% CI, 1.22-2.05) and at approximately 3 months (OR 1.61, 95% CI, 1.16-2.21). Using indirect comparisons, varenicline was superior to NRT when compared to placebo controls (OR 1.66, 95% CI 1.17-2.36, P = 0.004) or to all controls at 1 year (OR 1.73, 95% CI 1.22-2.45, P = 0.001). This was also the case for 3-month data. Adverse events were not systematically different across studies.
CONCLUSION:
NRT, bupropion and varenicline all provide therapeutic effects in assisting with smoking cessation. Direct and indirect comparisons identify a hierarchy of effectiveness.En ligne : https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-6-300 Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7965 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Effectiveness of stop smoking interventions among adults : an overview of systematic reviews Type de document : document électronique Auteurs : Mona Hersi, Auteur ; Andrew Beck, Auteur ; Candyce Hamel, Auteur Editeur : BioMed Central Année de publication : 2023 Collection : BMC Medicine, ISSN 1741-7015 num. 8(1) Importance : 21 p. Présentation : ill., tab. Langues : Anglais (eng) Catégories : [DIVERS] personne:par âge:adulte
[TABAC] chimie du tabac:tabac fumé:cigarette:cigarette électronique
[TABAC] étude:méta-analyse
[TABAC] sevrage tabagique:effet du sevrage:bénéfice du sevrage tabagique
[TABAC] tabagisme:risqueIndex. décimale : TA 6.10 Conséquences / effets à long-terme du sevrage Résumé : Background: Tobacco smoking is the leading cause of cancer, preventable death, and disability. Smoking cessation can increase life expectancy by nearly a decade if achieved in the third or fourth decades of life. Various stop smoking interventions are available including pharmacotherapies, electronic cigarettes, behavioural support, and alternative therapies. This protocol outlines an evidence review which will evaluate the benefits and harms of stop smoking interventions in adults.
Methods: The evidence review will consist of two stages. First, an overview of systematic reviews evaluating the benefits and harms of various stop smoking interventions delivered in or referred from the primary care setting will be conducted. The second stage will involve updating a systematic review on electronic cigarettes identified in the overview; randomized controlled trials will be considered for outcomes relating to benefits while randomized controlled trials, non-randomized controlled trials, and comparative observational studies will be considered for evaluating harms. Search strategies will be developed and peer-reviewed by medical information specialists. The search strategy for the updated review on e-cigarettes will be developed using that of the candidate systematic review. The MEDLINE®, PsycINFO, Embase, and the Cochrane Library electronic databases will be searched as of 2008 for the overview of reviews and from the last search date of the selected review for the updated review. Organizational websites and trial registries will be searched for unpublished or ongoing reviews/studies. Two reviewers will independently screen the title and abstracts of citations using the liberal accelerated method. Full-text screening will be performed independently by two reviewers. Extracted data will be verified by a second reviewer. Disagreements regarding full-text screening and data extraction will be resolved by consensus or third-party adjudication. The methodological quality of systematic reviews, risk of bias of randomized and non-randomized trials, and methodological quality of cohort studies will be evaluated using AMSTAR 2, the Cochrane risk of bias tool, and a modified version of the Scottish Intercollegiate Guidelines Network critical appraisal tool, respectively. The GRADE framework will be used to assess the quality of the evidence for outcomes.
Discussion: The evidence review will evaluate the benefits and harms of various stop smoking interventions for adults. Findings will be used to inform a national tobacco cessation guideline by the Canadian Task Force on Preventive Health Care.En ligne : https://doi.org/10.1186/s13643-018-0928-x Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10575 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Electronic cigarette use and smoking cessation in cohort studies and randomized trials : a systematic review and metaanalysis Type de document : document électronique Auteurs : Linnea Hedman, Auteur ; Maria Rosaria Galanti, Auteur ; Lotta Ryk, Auteur ; Hans Gilljam, Auteur ; Louise Adermark, Auteur Editeur : European Network for Smoking and Tobacco Prevention (ENSP) Année de publication : 2021 Collection : Tobacco Prevention & Cessation, ISSN 2459-3087 num. 7:62 Importance : 16 p. Présentation : ill. ; tab. ; graph. Langues : Anglais (eng) Catégories : [TABAC] chimie du tabac:tabac fumé:cigarette:cigarette électronique
[TABAC] étude:méta-analyse
[TABAC] sevrage tabagiqueIndex. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) Résumé : L'objectif de cette méta-analyse était d'évaluer l'association entre l'utilisation de l'e-cigarette et le sevrage tabagique ultérieur dans des études de cohorte et des essais contrôlés randomisés (ECR ou RCT).
En ligne : https://doi.org/10.18332/tpc/142320 Format de la ressource électronique : HTML, PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9439 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Impact of smoking on psoriasis risk and treatment efficacy : a meta-analysis Type de document : document électronique Auteurs : Hang Zhou, Auteur ; Ruifang Wu, Auteur ; Yi Kong, Auteur ; Ming Zhao, Auteur ; Yuwen Su, Auteur Editeur : Sage publications Année de publication : 2020 Collection : Journal of International Medical Research, ISSN 1473-2300 num. 48(11) Importance : p. 1-20 Présentation : ill., graph.; tab. Langues : Anglais (eng) Catégories : [TABAC] étude:méta-analyse
[TABAC] tabagisme:pathologie:pathologie dermatologique:psoriasis
[TABAC] tabagisme:risque
[TABAC] tabagisme:tabagisme actif:fumeurIndex. décimale : TA 3.2.2.6 Effets métaboliques et biologiques Résumé : Objective
Psoriasis is an immune-mediated chronic inflammatory disease with skin and joint manifestations. Smoking is considered an unfavorable lifestyle factor for psoriasis. We aimed to explore the association between smoking, disease risk, and treatment efficacy in relation to psoriasis.
Methods
We searched the Cochrane Library, Embase, and PubMed databases for studies examining the relationship between smoking and psoriasis, up to 12 April 2020. We then conducted a meta-analysis using a fixed-effects model to obtain odds ratios (ORs) with 95% confidence intervals (CIs).
Results
Ever, current, and former smokers all had higher risks of developing psoriasis than non-smokers (pooled ORs (95% CIs): 1.60 (1.51–1.69), 1.63 (1.48–1.80), and 1.36 (1.13–1.64), respectively). Ever smokers were less likely to show disease improvement at 6 months following treatment with biologic agents than non-smokers (pooled OR (95% CI): 0.80 (0.67–0.95)).
Conclusions
Smoking increases psoriasis risk and negatively impacts the benefits of biologic agents. However, the number of reports is limited and more studies are needed to confirm the effects of smoking and smoking cessation on therapeutic response in patients with psoriasis. Education to encourage a healthy lifestyle remains a valuable approach in clinical practice.En ligne : https://doi.org/10.1177/0300060520964024 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10592 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Interventions comportementales dans le sevrage tabagique : synthèse et méta‐analyse en réseau Titre original : Behavioural interventions for smoking cessation: an overview and network meta‐analysis Type de document : document électronique Auteurs : Jamie Hartmann-Boyce, Auteur ; Jonathan Livingstone-Banks, Auteur ; José Ordóñez-Mena, Auteur Editeur : The Cochrane Collaboration Année de publication : 2021 Collection : Cochrane Database of Systematic Reviews num. 1 Importance : 52 p. Présentation : ill. ; tab. ; graph. Langues : Français (fre) Langues originales : Anglais (eng) Catégories : [TABAC] étude:méta-analyse
[TABAC] sevrage tabagique:effet du sevrage
[TABAC] sevrage tabagique:efficacité du sevrage
[TABAC] tabagisme:aspect psychologique:comportementIndex. décimale : TA 6 Sevrage tabagique Résumé : Le tabagisme est l'une des principales causes de maladie et de décès dans le monde. Chez les fumeurs, l'arrêt du tabac peut inverser une grande partie des dommages. De nombreuses personnes ont recours à des interventions comportementales pour les aider à arrêter de fumer ; ces interventions peuvent varier considérablement dans leur contenu et leur efficacité. En ligne : https://doi.org/10.1002/14651858.CD013229.pub2 Format de la ressource électronique : Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9915 Est accompagné deAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : A meta-analysis of electric cigarette use and lung health implications Type de document : document électronique Auteurs : Rika Florensia, Auteur ; Fauzar, Auteur ; Roza Kurniati, Auteur Editeur : HM Publisher Année de publication : 2024 Collection : Bioscientia Medicina: Journal of Biomedicine & Translational Research, ISSN 2598-0580 num. 8(10) Importance : p. 5160-5171 Présentation : tab. Langues : Anglais (eng) Catégories : [DIVERS] anatomie:corps humain:appareil respiratoire
[TABAC] chimie du tabac:tabac fumé:cigarette:cigarette électronique
[TABAC] étude:méta-analyse
[TABAC] tabagisme:pathologie:pathologie respiratoire
[TABAC] tabagisme:risqueIndex. décimale : TA 3.2.2.4 Pathologies respiratoires (sauf 3.2.2.1, 3.2.2.2, 3.2.2.3) Résumé : Background: The global rise in electric cigarette (e-cigarette) use has prompted urgent investigation into their health effects. This meta-analysis aims to consolidate evidence regarding the impact of e-cigarette use on lung health.
Methods: A systematic search of PubMed, Embase, and Cochrane Library databases was conducted, identifying studies published between 2018 and 2024 that assessed lung function, respiratory symptoms, and lung disease incidence in e-cigarette users. Studies meeting inclusion criteria were subjected to quality assessment and data extraction. Random-effects models were used for pooled analysis, and heterogeneity was assessed.
Results: Twenty-three studies, encompassing 12,456 participants, were included. E-cigarette use was associated with a small but significant decrease in forced expiratory volume in 1 second (FEV1) (standardized mean difference [SMD] -0.18, 95% CI -0.26 to -0.10, p<0.001). Increased odds of wheezing (odds ratio [OR] 1.38, 95% CI 1.15 to 1.65, p=0.001) and chronic cough (OR 1.25, 95% CI 1.08 to 1.44, p=0.003) were also observed in e-cigarette users. No significant association was found with chronic obstructive pulmonary disease (COPD) incidence.
Conclusion: E-cigarette use appears detrimental to lung function and associated with respiratory symptoms. Further long-term research is imperative to establish definitive conclusions on the risk of COPD and other lung diseases.En ligne : https://doi.org/10.37275/bsm.v8i10.1099 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10499 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Pharmacological interventions for smoking cessation : an overview and network meta-analysis (review) Type de document : texte imprimé Auteurs : Kate Cahill, Auteur ; S. Stevens, Auteur ; T. Lancaster, Auteur ; R. Perera, Auteur Editeur : The Cochrane Collaboration Année de publication : 2013 Collection : Cochrane Database of Systematic Reviews num. issue 5 Importance : 49 p. Langues : Français (fre) Catégories : [TABAC] étude:méta-analyse
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologiqueIndex. décimale : TA 6.2.3 Approche pharmacologique Résumé : Abstract
Background
Smoking is the leading preventable cause of illness and premature death worldwide. Some medications have been proven to help people to quit, with three licensed for this purpose in Europe and the USA: nicotine replacement therapy (NRT), bupropion, and varenicline. Cytisine (a treatment pharmacologically similar to varenicline) is also licensed for use in Russia and some of the former socialist economy countries. Other therapies, including nortriptyline, have also been tested for effectiveness.
Objectives
How do NRT, bupropion and varenicline compare with placebo and with each other in achieving long-term abstinence (six months or longer)?
How do the remaining treatments compare with placebo in achieving long-term abstinence?
How do the risks of adverse and serious adverse events (SAEs) compare between the treatments, and are there instances where the harms may outweigh the benefits?
Methods
The overview is restricted to Cochrane reviews, all of which include randomised trials. Participants are usually adult smokers, but we exclude reviews of smoking cessation for pregnant women and in particular disease groups or specific settings. We cover nicotine replacement therapy (NRT), antidepressants (bupropion and nortriptyline), nicotine receptor partial agonists (varenicline and cytisine), anxiolytics, selective type 1 cannabinoid receptor antagonists (rimonabant), clonidine, lobeline, dianicline, mecamylamine, Nicobrevin, opioid antagonists, nicotine vaccines, and silver acetate. Our outcome for benefit is continuous or prolonged abstinence at least six months from the start of treatment. Our outcome for harms is the incidence of serious adverse events associated with each of the treatments.
We searched the Cochrane Database of Systematic Reviews (CDSR) in The Cochrane Library, for any reviews with 'smoking' in the title, abstract or keyword fields. The last search was conducted in November 2012. We assessed methodological quality using a revised version of the AMSTAR scale. For NRT, bupropion and varenicline we conducted network meta-analyses, comparing each with the others and with placebo for benefit, and varenicline and bupropion for risks of serious adverse events.
Main results
We identified 12 treatment-specific reviews. The analyses covered 267 studies, involving 101,804 participants. Both NRT and bupropion were superior to placebo (odds ratios (OR) 1.84; 95% credible interval (CredI) 1.71 to 1.99, and 1.82; 95% CredI 1.60 to 2.06 respectively). Varenicline increased the odds of quitting compared with placebo (OR 2.88; 95% CredI 2.40 to 3.47). Head-to-head comparisons between bupropion and NRT showed equal efficacy (OR 0.99; 95% CredI 0.86 to 1.13). Varenicline was superior to single forms of NRT (OR 1.57; 95% CredI 1.29 to 1.91), and to bupropion (OR 1.59; 95% CredI 1.29 to 1.96).
Varenicline was more effective than nicotine patch (OR 1.51; 95% CredI 1.22 to 1.87), than nicotine gum (OR 1.72; 95% CredI 1.38 to 2.13), and than 'other' NRT (inhaler, spray, tablets, lozenges; OR 1.42; 95% CredI 1.12 to 1.79), but was not more effective than combination NRT (OR 1.06; 95% CredI 0.75 to 1.48). Combination NRT also outperformed single formulations. The four categories of NRT performed similarly against each other, apart from 'other' NRT, which was marginally more effective than NRT gum (OR 1.21; 95% CredI 1.01 to 1.46).
Cytisine (a nicotine receptor partial agonist) returned positive findings (risk ratio (RR) 3.98; 95% CI 2.01 to 7.87), without significant adverse events or SAEs.
Across the 82 included and excluded bupropion trials, our estimate of six seizures in the bupropion arms versus none in the placebo arms was lower than the expected rate (1:1000), at about 1:1500. SAE meta-analysis of the bupropion studies demonstrated no excess of neuropsychiatric (RR 0.88; 95% CI 0.31 to 2.50) or cardiovascular events (RR 0.77; 95% CI 0.37 to 1.59). SAE meta-analysis of 14 varenicline trials found no difference between the varenicline and placebo arms (RR 1.06; 95% CI 0.72 to 1.55), and subgroup analyses detected no significant excess of neuropsychiatric events (RR 0.53; 95% CI 0.17 to 1.67), or of cardiac events (RR 1.26; 95% CI 0.62 to 2.56).
Nortriptyline increased the chances of quitting (RR 2.03; 95% CI 1.48 to 2.78). Neither nortriptyline nor bupropion were shown to enhance the effect of NRT compared with NRT alone. Clonidine increased the chances of quitting (RR 1.63; 95% CI 1.22 to 2.18), but this was offset by a dose-dependent rise in adverse events. Mecamylamine in combination with NRT may increase the chances of quitting, but the current evidence is inconclusive. Other treatments failed to demonstrate a benefit compared with placebo. Nicotine vaccines are not yet licensed for use as an aid to smoking cessation or relapse prevention. Nicobrevin's UK license is now revoked, and the manufacturers of rimonabant, taranabant and dianicline are no longer supporting the development or testing of these treatments.
Authors' conclusions
NRT, bupropion, varenicline and cytisine have been shown to improve the chances of quitting. Combination NRT and varenicline are equally effective as quitting aids. Nortriptyline also improves the chances of quitting. On current evidence, none of the treatments appear to have an incidence of adverse events that would mitigate their use.
Further research is warranted into the safety of varenicline and into cytisine's potential as an effective and affordable treatment, but not into the efficacy and safety of NRT.En ligne : https://doi.org/10.1002/14651858.CD009329.pub2 Format de la ressource électronique : HTML, PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7444 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Phenomenon of vaping in generation Z women Type de document : document électronique Auteurs : Teuku Renaldi, Auteur ; Agung Pranata, Auteur ; Rima Novirianty, Auteur Editeur : LPPM Unsyiah Année de publication : 2024 Collection : Trends in Infection and Global Health, ISSN 2807-646X num. 4(1) Importance : p. 10-16 Présentation : tab. Langues : Anglais (eng) Catégories : [DIVERS] personne:par âge:jeune
[DIVERS] personne:par sexe:femme
[TABAC] chimie du tabac:tabac fumé:cigarette:cigarette électronique
[TABAC] économie du tabac:marketing:publicité
[TABAC] étude:méta-analyseIndex. décimale : TA 2.4.2 Femmes Résumé : The vaping phenomenon among Generation Z (Gen Z) women has increased in popularity as an alternative to traditional cigarettes. As a group that has grown up in the digital era, they have easier access to information via the internet and social media, which has influenced their lifestyles and choices, including when it comes to smoking and vaping. The aim of this study was to understand how the vaping phenomenon affects Gen Z women. To address this question, our research provides an overview of the vaping-related phenomena occurring among Gen Z women. We conducted a literature review of eight publications covering five years, 2019–2024. The data indicated phenomena such as an increase in the number of vape users among women and an increase in aggressive vape advertising. Our study also explored the factors that lead to this phenomenon occurring and how the surrounding environment plays a very large role in this issue. Data suggested that the increase in vaping among Gen Z women is primarily due to environmental and peer influence factors. Therefore, to have better prevention and intervention strategies, peer influence should be taken into account. En ligne : https://jurnal.usk.ac.id/TIGH/article/view/39144 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10495 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Risk of serious adverse cardiovascular events associated with varenicline : a systematic review and meta-analysis Type de document : texte imprimé Auteurs : Sonal Singh, Auteur ; Yoon K. Loke, Auteur ; John G. Spangler, Auteur ; Curt D. Furberg, Auteur Année de publication : 2011 Importance : 8 p. Langues : Anglais (eng) Catégories : [DIVERS] anatomie:corps humain:appareil circulatoire:cœur
[TABAC] étude:méta-analyse
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:effet secondaire
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.2 Autres produits Résumé : CONTEXTE:
Des événements cardiovasculaires indésirables associés à l'utilisation de la varénicline, un médicament anti-tabac largement utilisé, ont été rapportés après la commercialisation. Nous avons effectué une revue systématique et une méta-analyse d'essais contrôlés randomisés pour déterminer les effets cardiovasculaires indésirables graves de la varénicline par rapport au placebo chez les consommateurs de tabac.
MÉTHODES:
Nous avons cherché dans MEDLINE, EMBASE, la base de données de revues systématiques Cochrane, les sites Web d'autorités de réglementation et les registres d'essais cliniques, sans restriction de date ou de langue, jusqu'en septembre 2010 (mise à jour en mars 2011) pour les études publiées et non publiées. Nous avons sélectionné des essais contrôlés randomisés en double aveugle d'une durée d'au moins une semaine impliquant des fumeurs ou des personnes ayant consommé du tabac sans fumée et rapportant des événements cardiovasculaires (ischémie, arythmie, insuffisance cardiaque congestive, mort subite ou décès d'origine cardiovasculaire) comme événements indésirables graves associés à l'utilisation de la varénicline.
RÉSULTATS:
Nous avons analysé les données de 14 essais contrôlés randomisés à double insu portant sur 8 216 participants. Les essais ont duré de 7 à 52 semaines. La varénicline était associée à un risque significativement accru d'événements cardiovasculaires indésirables graves par rapport au placebo (1,06% [52/4908] dans le groupe varénicline vs 0,82% [27/3308] dans le groupe placebo; rapport de cotes de Peto [OR] 1,72, 95% intervalle de confiance [IC] 1,09-2,71; I (2) = 0%). Les résultats de diverses analyses de sensibilité concordaient avec ceux de l'analyse principale et un graphique en entonnoir n'a révélé aucun biais de publication. Il y avait trop peu de décès pour permettre des comparaisons significatives de la mortalité.
INTERPRÉTATION:
Notre méta-analyse soulève des préoccupations en matière de sécurité quant à la possibilité d'un risque accru d'événements cardiovasculaires indésirables graves associés à l'utilisation de varénicline chez les consommateurs de tabac.En ligne : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3168618/ Format de la ressource électronique : HTML, PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8830 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Smoking cessation and short- and longer-term mortality Type de document : document électronique Auteurs : Eo Rin Cho, Auteur ; Ilene K. Brill, Auteur ; Inger T Gram, Auteur ; Patrick E Brown, Auteur ; Jha Prabhat, Auteur Année de publication : 2024 Importance : 3 p. Langues : Anglais (eng) Catégories : [TABAC] étude:méta-analyse
[TABAC] étude:statistique:mortalité
[TABAC] sevrage tabagiqueIndex. décimale : TA 3.2.1 Mortalité Résumé : BACKGROUND
Smoking cessation reduces mortality and morbidity. However, the extent and rapidity at which cessation reduces contemporary death rates from smoking-related illnesses remain uncertain.
METHODS
We pooled current or former versus never cigarette smoker hazard ratios from four national cohorts with linkage to death registries in the United States, United Kingdom, Norway, and
Canada among adults 20 to 79 years of age from 1974 to 2018. We calculated excess risk differences and survival, comparing current or never smokers with age-specific cessation and
cessation fewer than 3, 3 to 9, or 10 or more years earlier.
RESULTS
Among 1.48 million adults followed for 15 years, 122,697 deaths occurred. Adjusting for age, education, alcohol use, and obesity, current smokers had higher hazard ratios for death
compared with never smokersEn ligne : https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300272 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10222 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Smoking cessation interventions for patients with depression : a systematic review and meta-analysis Type de document : texte imprimé Auteurs : Jennifer M. Gierisch, Auteur ; Lori A. Bastian, Auteur ; Patrick S. Calhoun, Auteur ; Jennifer R. McDuffie, Auteur Editeur : Society of General Internal Medicine Année de publication : 2011 Collection : Journal of general internal Medicine num. 27:3 Importance : p. 351-360 Présentation : tab., graph. Langues : Anglais (eng) Catégories : [TABAC] étude:méta-analyse
[TABAC] sevrage tabagique:méthode de sevrage
[TABAC] tabagisme:effet du tabac:effet psychiatrique:dépressionIndex. décimale : TA 6.2 Méthodes individuelles Résumé : BJECTIVES:
We conducted a systematic literature review of smoking cessation interventions for patients with histories of depressive disorders or current significant depressive symptoms. We examined the comparative effectiveness of smoking cessation strategies on abstinence rates, differential effects of cessation strategies by depression status (i.e., history positive vs. current depression), and differential effects by gender.
DATA SOURCES:
Peer-reviewed literature in MEDLINE, Embase, PsycINFO, and Cochrane Library.
STUDY ELIGIBILITY CRITERIA, PARTICIPANTS, AND INTERVENTIONS:
Randomized controlled trials or secondary analysis of RCT data comparing two or more smoking cessation interventions or intervention to control, and reporting cessation outcomes in adults with depression.
STUDY APPRAISAL AND SYNTHESIS METHODS:
Two trained researchers screened articles for inclusion. When possible, we estimated pooled risk ratios with 95% confidence intervals by using a random effects model with the Mantel-Haenszel method. We synthesized other studies qualitatively. We classified each intervention as antidepressants, nicotine replacement therapy (NRT), brief smoking cessation counseling, smoking cessation behavioral counseling, or behavioral mood management.
RESULTS:
We identified 16 unique RCTs, of which, only three trials recruited participants with current depression. Meta-analysis demonstrated a small, positive effect of adding behavioral mood management (RR = 1.41, 95% CI 1.01-1.96). All included antidepressant trials showed small, positive effects, but risk ratio summary was not significant (RR = 1.31, 95% CI 0.73-2.34). Three NRT trials demonstrated small, positive effects on smoking cessation rates. We found insufficient evidence to examine gender and depression status moderator effects.
LIMITATIONS:
Few RCTs exist that test smoking cessation interventions among adults with depression. To make meaningful comparisons, we created broad intervention categories that contained heterogeneity.
CONCLUSIONS AND IMPLICATIONS OF KEY FINDINGS:
Few trials enrolled smokers with current depression. Most of data identified were from subgroup analyses of patients history-positive for depression. However, several promising interventions exist. Healthcare providers should consider encouraging their patients with significant depressive symptoms or depression histories to seek smoking cessation services that include NRT and behavioral mood management.Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8092 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
